antoniofagundesjr (@fagundes_anton) 's Twitter Profile
antoniofagundesjr

@fagundes_anton

Intesivist/Cardiologist, #Zentensivist, father and science lover. ICU Chair, DFStar Hospital Researcher at IDOR Research Institute

ID: 960340437289656320

calendar_today05-02-2018 02:32:57

778 Tweet

234 Followers

1,1K Following

TIMI Study Group (@timistudygroup) 's Twitter Profile Photo

Primary results from Bridge-TIMI 73a Late Breaking Clinical Trial presented by Brian Bergmark at #ACC24 show that #olezarsen reduces #triglyceride levels by ~50% without major safety concerns. Now published in NEJM. Nicholas Marston

Primary results from Bridge-TIMI 73a Late Breaking Clinical Trial presented by <a href="/BrianBergmark/">Brian Bergmark</a> at #ACC24 show that #olezarsen reduces #triglyceride levels by ~50% without major safety concerns. Now published in <a href="/NEJM/">NEJM</a>. <a href="/marstonMD/">Nicholas Marston</a>
NEJM (@nejm) 's Twitter Profile Photo

Presented today at #ACC24: In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

Presented today at #ACC24: 

In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t
NEJM (@nejm) 's Twitter Profile Photo

Presented at #ACC24: Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx

Presented at #ACC24:

Hospitalized patients with acute myocardial infarction &amp; preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx
Muthu Vaduganathan (@mvaduganathan) 's Twitter Profile Photo

#ACC24 #SimPub in Circulation by Sid M. Patel & #SMARTc investigators Massive effort evaluating 78,607 patients across 11 late-phase trials in diabetes, CKD, & HF providing definitive evidence of the effects of #SGLT2i on #MACE ahajournals.org/doi/10.1161/CI…

#ACC24 #SimPub in <a href="/CircAHA/">Circulation</a> by <a href="/SidPatelMD/">Sid M. Patel</a> &amp; #SMARTc investigators 

Massive effort evaluating 78,607 patients across 11 late-phase trials in diabetes, CKD, &amp; HF providing definitive evidence of the effects of #SGLT2i on #MACE

ahajournals.org/doi/10.1161/CI…
NEJM (@nejm) 's Twitter Profile Photo

Of 30 patients with severe #SickleCellDisease who were treated with gene-edited autologous hematopoietic stem and progenitor cells, 29 were free from vaso-occlusive crises for at least 12 consecutive months. Read the full CLIMB SCD-121 study results: nej.md/3UvzPDT

Of 30 patients with severe #SickleCellDisease who were treated with gene-edited autologous hematopoietic stem and progenitor cells, 29 were free from vaso-occlusive crises for at least 12 consecutive months. Read the full CLIMB SCD-121 study results: nej.md/3UvzPDT
JACC Journals (@jaccjournals) 's Twitter Profile Photo

#AHA24: How does the benefit of microaxial flow pumps in cardiogenic shock vary by age? In a new analysis of the DanGer Shock trial, Dr. Jacob Møller & team at Research Unit of Cardiology, OUH find that these devices may not benefit older patients (>77 y/o) bit.ly/3Z56S3L #JACC #cvGeri

#AHA24: How does the benefit of microaxial flow pumps in cardiogenic shock vary by age? In a new analysis of the DanGer Shock trial, Dr. Jacob Møller &amp; team at <a href="/CardResearchOuh/">Research Unit of Cardiology, OUH</a> find that these devices may not benefit older patients (&gt;77 y/o) bit.ly/3Z56S3L

#JACC #cvGeri
Critical Care Reviews (@critcarereviews) 's Twitter Profile Photo

Decoding VExUS: a practical guide for excelling in point-of-care ultrasound assessment of venous congestion CCR Journal Watch criticalcarereviews.com/latest-evidenc… Get the latest critical care literature every weekend via the CCR Newsletter - subscribe at criticalcarereviews.com/newsletters/su…

Decoding VExUS: a practical guide for excelling in point-of-care ultrasound assessment of venous congestion

CCR Journal Watch
criticalcarereviews.com/latest-evidenc…

Get the latest critical care literature every weekend via the CCR Newsletter - subscribe at criticalcarereviews.com/newsletters/su…
Francesco Paneni (@francescopaneni) 's Twitter Profile Photo

Celebrating the 95th birthday of Prof. Eugene Braunwald. Look at the areas where he contributed the most👇❤️ #Leaders #Cardiology

Celebrating the 95th birthday of Prof. Eugene Braunwald. Look at the areas where he contributed the most👇❤️ #Leaders #Cardiology
antoniofagundesjr (@fagundes_anton) 's Twitter Profile Photo

Part of the history of modern cardiology is in this photo. Dr. Braunwald, the father of cardiology as we know it, at his 95 years, fully active; Dr. Peter Libby, the pope of atherosclerosis; Dr. Marc Pfeffer, the king of heart failure. Masters who inspired me and inspire me.

Part of the history of modern cardiology is in this photo. Dr. Braunwald, the father of cardiology as we know it, at his 95 years, fully active; Dr. Peter Libby, the pope of atherosclerosis; Dr. Marc Pfeffer, the king of heart failure. Masters who inspired me and inspire me.
TIMI Study Group (@timistudygroup) 's Twitter Profile Photo

Drs. Eugene Braunwald and Marc Sabatine giving Cardiovascular Grand Rounds Brigham and Women's Hospital on the 40th anniversary of the TIMI Study Group. timi.org/timis-40th-ann…

Drs. Eugene Braunwald and Marc Sabatine giving Cardiovascular Grand Rounds <a href="/BrighamWomens/">Brigham and Women's Hospital</a> on the 40th anniversary of the TIMI Study Group. timi.org/timis-40th-ann…
Intensive Care Medicine (@youricm) 's Twitter Profile Photo

◾️In memory of Prof L Gattinoni, towering figure in ICM, profoundly shaping understanding of #ARDS & #ECMO. The “father" of prone position revolutionized MV with a pioneering "baby lung” concept. His legacy will guide/inspire for generations to come. 🔗esicm.org/obituary-lucia…

◾️In memory of Prof L Gattinoni, towering figure in ICM, profoundly shaping understanding of #ARDS &amp; #ECMO. The “father" of prone position revolutionized MV with a pioneering "baby lung” concept. His legacy will guide/inspire for generations to come.
🔗esicm.org/obituary-lucia…
Dr Alo, DO, FACC (@mohammedalo) 's Twitter Profile Photo

LDL-C, hsCRP, Lp(a), and CVD Risk 1️⃣ Risk scores and imaging show whom to treat; blood biomarkers reveal what to target. 2️⃣ This new study tracked LDL, hsCRP, and Lp(a) in 17,087 people over 20 years for major cardiovascular events. 3️⃣ Higher levels of Ldl-c, hsCRP, and Lp(a)

LDL-C, hsCRP, Lp(a), and CVD Risk

1️⃣ Risk scores and imaging show whom to treat; blood biomarkers reveal what to target.

2️⃣ This new study tracked LDL, hsCRP, and Lp(a) in 17,087 people over 20 years for major cardiovascular events.

3️⃣ Higher levels of Ldl-c, hsCRP, and Lp(a)
ANZICS (@anzics) 's Twitter Profile Photo

Dear friends and colleagues, It is with overwhelming sadness that we share news of the death of our colleague, mentor and friend, Rinaldo Bellomo. During recent days, both he and his family have received dedicated, expert and compassionate care from some of the finest in our ICU

Dear friends and colleagues,

It is with overwhelming sadness that we share news of the death of our colleague, mentor and friend, Rinaldo Bellomo. During recent days, both he and his family have received dedicated, expert and compassionate care from some of the finest in our ICU
John Mandrola, MD (@drjohnm) 's Twitter Profile Photo

This is such an important observation. On many levels. I will discuss on This Week in Cardiology. Teaser thoughts: A) Recall that as treatment of a problem gets better, screening becomes less important. B) All humans die; so if they don't die of cancer and AMI, that leaves